Analyst Price Target is $12.63
▲ +31.51% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for Profound Medical in the last 3 months. The average price target is $12.63, with a high forecast of $20.00 and a low forecast of $6.50. The average price target represents a 31.51% upside from the last price of $9.60.
Current Consensus is
The current consensus among 3 contributing investment analysts is to buy stock in Profound Medical. This Buy consensus rating has held steady for over two years.
Profound Medical Corp., together with its subsidiaries, operates as a commercial-stage medical device company that develops and markets incision-free therapeutic systems for the image guided ablation of diseased tissue in Canada, Germany, the United States, and Finland. Its lead product TULSA-PRO system combines magnetic resonance imaging(MRI), robotically-driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to provide precise, flexible, and durable ablation of a surgeon defined region of prostate and protect the urethra and rectum. The company also offers Sonalleve, which combines real-time MRI and thermometry for the treatment of uterine fibroids, palliative pain treatment of bone metastases, and osteoid osteoma. Profound Medical Corp. is headquartered in Mississauga, Canada.